Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Tislelizumab, Pamiparib, and Other Agents in Advanced Malignancies
NCT04164199Phase 3Completed
- Sponsor
- BeOne Medicines
- Start
- Dec 2019
- Primary completion
- May 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of tislelizumab, pamiparib in advanced cancer, sponsored by BeOne Medicines. Started Dec 2019; status: completed.
02
Drugs
tislelizumabpamiparib
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT04164199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164199.